Inquiry Basket
Loading ......
Filter By Product Search for
NiV F Protein
NiV F Protein Full Name
Nipah virus Fusion glycoprotein F1
NiV F Protein Introduction
The Nipah virus (NiV) F glycoprotein is a class I viral fusion protein that plays a central role in viral entry by mediating membrane fusion following activation by the attachment protein G. Structurally, NiV F is synthesized as a precursor (F0) that undergoes cathepsin L–dependent cleavage into F1 and F2 subunits, a maturation step required for fusion competence. On the virion surface, NiV F forms a metastable trimer in the prefusion conformation. The F1 subunit contains the hydrophobic fusion peptide and two heptad repeat regions (HR1 and HR2) that refold into a six-helix bundle during the transition to the postfusion state, driving membrane merger. This prefusion-to-postfusion transformation is the fundamental mechanistic event underlying viral entry. Importantly, structural studies across henipaviruses reveal that the prefusion conformation of NiV F is conformationally constrained yet energetically poised for triggering, making it inherently unstable but immunologically rich. The majority of potent neutralizing epitopes reside on the prefusion trimer—particularly at the apex and quaternary interfaces—while many of these epitopes are lost or rearranged in the postfusion structure. This architecture establishes prefusion NiV F as both the functional core of membrane fusion and the most relevant antigenic target for vaccine development.
Figure 1. Schematic representation of the viral structure and genome organization. (Source: Sun B, et al. 2018)
The triggering of NiV F is tightly coordinated with receptor engagement by the NiV G attachment protein. Binding of G to ephrin-B2 or ephrin-B3 initiates an allosteric cascade that propagates from G to F, priming F for its conformational transition. Evidence supports a cooperative G–F interface in which both the head and stalk regions of G contribute to F activation. Upon receptor binding, F undergoes a sequence of structural rearrangements that includes exposure of the fusion peptide, formation of a prehairpin intermediate, and eventual collapse into the stable six-helix bundle of the postfusion state. Biochemical and kinetic analyses indicate that receptor engagement accelerates this cascade, and mutations in either G or F can modulate the rate and efficiency of triggering. Importantly, the prefusion form represents a metastable intermediate that is structurally primed yet not yet committed to fusion, making it an ideal point for immune intervention. Stabilization strategies aim to "lock" the F trimer in this prefusion conformation, preventing premature rearrangement while preserving neutralizing epitopes. Disulfide engineering near the fusion peptide, substitutions in base regions, and optimized trimerization scaffolds have proven effective in maintaining prefusion architecture. Notably, some of these stabilizing principles are transferable across henipaviruses—including Hendra virus (HeV) and Langya virus (LayV)—although sequence-specific optimization is often required. These findings highlight a conserved structural vulnerability within henipavirus F proteins that can be exploited for broad vaccine design.
The immunological and translational implications of prefusion NiV F are substantial. Prefusion-stabilized F immunogens consistently elicit higher neutralizing antibody titers than postfusion F constructs in animal models. Monoclonal antibodies targeting prefusion-specific epitopes—particularly apex and quaternary epitopes—demonstrate potent neutralization and protective efficacy in vivo, validating the prefusion conformation as a superior vaccine antigen. Antibody strategies that stabilize F in prefusion or trap prehairpin intermediates further illustrate mechanistic avenues for both prophylaxis and post-exposure therapy. From a vaccine design perspective, soluble F trimers fused to heterologous trimerization domains have been used to recapitulate native prefusion epitopes, though careful validation is required to ensure authentic antigen presentation. Emerging structural and imaging studies also suggest that nanoscale organization and membrane context influence epitope exposure and functional triggering, implying that antigen design must consider higher-order assembly as well as primary sequence. While there are nuanced differences in how stabilization mutations transfer among NiV, HeV, and LayV F proteins, the overarching consensus is clear: prefusion-focused strategies provide superior immunogenicity and neutralization breadth. Leveraging structural knowledge of NiV F transformation—particularly the metastable prefusion state and its apex vulnerabilities—represents a rational and robust framework for developing next-generation vaccines and therapeutic antibodies against Nipah virus and related henipaviruses.
Alternate Names for NiV F Protein
Nipah virus; Nipah henipavirus; NiV; Paramyxoviridae; Henipavirus; Nipah virus F F1; NiV F F1; Fusion glycoprotein; Protein F;Nipah virus Fusion glycoprotein F1;NiV Fusion glycoprotein F1
Loading ......
